ZHENG Yangqin,YIN Weiyong,ZHOU Chengye. Efficacy and safety of dabigatran for secondary prevention of stroke in patients with non-valvular atrial fibrillation[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(5): 383-387.
Abstract：Objective: To compare dabigatran and warfarin for secondary stroke prevention in nonvalvular atrial fibrillation patients in efficacy and safety. Methods: Patients diagnosed as ischemic stroke with NVAF in our hospital from January 2013 to January 2015 were continuously reviewed, which were divided into two groups, anticoagulated with dabigatran 110 mg twice daily and adjusted-dose warfarin. The occurrence of stroke and systemic embolism, any bleeding, adverse reactions were recorded. Results: Systemic embolism occurred in 11 patients on warfarin compared with 3 on dabigatran (P<0.05 for noninferiority). Has-bled was a predictor of major bleeding on warfarin (P<0.05), but not of dabigatran (P>0.05). Conclusion: In patients with NVAF, dabigatran given at a dose of 110 mg is associated with lower rates of systemic embolism. Has-bled may be not suitable for dabigatran, and it needs to be refined.
